Osimertinib (Tagrisso®)

DRUG2 trials

Sponsors

Boehringer Ingelheim, Wayshine Biopharm, Inc.

Conditions

Non Small Cell Lung Cancer (NSCLC)Non-squamous, Non-Small Cell Lung Cancer

Phase 1

A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC

RecruitingNCT07206498

Wayshine Biopharm, Inc.Non Small Cell Lung Cancer (NSCLC)

Start: 2025-10-17End: 2029-10-14Target: 48Updated: 2025-11-28

Unknown Phase

The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib

CompletedNCT04179890

Boehringer IngelheimNon-squamous, Non-Small Cell Lung Cancer

Start: 2019-12-17End: 2021-07-22Updated: 2023-05-25

Related Papers

Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon <i>EGFR</i> Mutations: A Retrospective International Cohort Study (UpSwinG)

The Oncologist2022-01-2724 citations

Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG).

2021-09-2124 citations

Abstract LB138: UpSwinG: real-world, non-interventional cohort study on TKI activity in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations

Cancer Research2021-07-011 citations

Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon <i>EGFR</i> mutations: A real-world cohort study (UpSwinG).

Journal of Clinical Oncology2021-05-20